logo
Vizient Hosts Congressional Briefing on the Complexities of Hospital Financing

Vizient Hosts Congressional Briefing on the Complexities of Hospital Financing

Business Wire15-05-2025
IRVING, Texas--(BUSINESS WIRE)--Yesterday on Capitol Hill, Vizient, Inc. hosted a congressional policy briefing titled, "Hospitals' Financial Health: The Complex Ecosystem of Provider Reimbursement," at the Rayburn House Office Building. The event featured remarks from Rep. Dave Min (D-CA) and drew an engaged audience of congressional staff and industry stakeholders. While unable to attend in person, House Agriculture Committee Chairman Glenn 'GT' Thompson (R-PA) and Rep. Lou Correa (D-CA) shared remarks in support of the briefing. The discussion focused on how hospitals are navigating a complex financial environment shaped by shifting reimbursement models, evolving policy changes, and increasing care demands.
'Academic medical centers like UCI Health are training future clinicians while delivering essential care,' said Rep. Min (D-CA). 'However, growing financial pressures, especially around Medicaid reimbursement, threaten their ability to keep their doors open. We need to advance policies that ensure reliable reimbursement and protect access to care for all Californians.'
'As a former therapist and licensed nursing home administrator, I've seen first-hand the essential need for access to quality care,' said Rep. Thompson (R-PA). 'Reliable health systems are necessary for the health and economic well-being of rural communities. I look forward to working with all stakeholders to strengthen quality, lower costs, and increase the availability of care.'
'In neighborhoods across Orange County, hospitals are essential for delivering care, supporting jobs, and keeping our families healthy,' said Rep. Correa (D-CA). 'When hospitals in our district face financial strain, the ripple effects are real and immediate. We need strong, common-sense public policy that ensures hard-working American taxpayers have access to the care they need when they need it.'
Moderated by Michael D. Busch, FACHE, senior vice president, member networks at Vizient, the panel featured key healthcare leaders, including:
Stephanie Daubert, Chief Financial Officer, Nebraska Medicine
Steven M. Fontaine, Chief Executive Officer, Penn Highlands Healthcare
Randolph P. Siwabessy, Senior Vice President & Chief Financial Officer, UCI Health & UC Irvine School of Medicine
Panelists discussed the growing financial instability facing hospitals, particularly given the uncertainty around governmental funding. As noted during the briefing, hospitals are a unique combination of public utility, clinical enterprise, and academic mission, which makes their financing inherently complex. Adjusting one policy can unintentionally unravel other parts due to the system's interconnectedness. Panelists also highlighted rising operating costs, persistent labor shortages, delayed reimbursements, and the widening gap between payment rates and the actual cost of care, especially for Medicaid and Medicare patients.
The panel underscored the need for sustainable policy solutions to protect hospital viability and patient access, highlighting priorities such as stabilizing government reimbursement programs, protecting safety net payments and programs and preserving graduate medical education support.
Learn more about Vizient's advocacy and public policy efforts.
About Vizient, Inc.
Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Citi Remains Bullish on Sana Biotechnology (SANA)
Citi Remains Bullish on Sana Biotechnology (SANA)

Yahoo

time26 minutes ago

  • Yahoo

Citi Remains Bullish on Sana Biotechnology (SANA)

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best biotech penny stocks to buy right now. Citi analyst Samantha Semenkow maintained a bullish stance on Sana Biotechnology, Inc. (NASDAQ:SANA), giving it a Buy rating on July 2 with a $15 price target. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. The analyst based the rating on Sana Biotechnology, Inc.'s (NASDAQ:SANA) potential in addressing notable market opportunities. Semenkow stated that the company's Type 1 Diabetes (T1D) program has exhibited considerable proof-of-concept results, with updated six-month data showing durable c-peptide production and successful graft survival without the need for immunosuppression. According to the analyst, this data consistency bolsters confidence in Sana Biotechnology, Inc.'s (NASDAQ:SANA) approach and paints a positive picture for its T1D asset, SC451, anticipated to make progress towards an IND as early as 2026. The same day, Morgan Stanley analyst Maxwell Skor also assumed coverage of Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and $12 price target. The analyst expects an investigational new drug filing as early as next year for its proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Oppenheimer Reduces PT on UnitedHealth Group (UNH) Stock
Oppenheimer Reduces PT on UnitedHealth Group (UNH) Stock

Yahoo

time36 minutes ago

  • Yahoo

Oppenheimer Reduces PT on UnitedHealth Group (UNH) Stock

UnitedHealth Group Incorporated (NYSE:UNH) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 30, Oppenheimer analyst Michael Wiederhorn reduced the price objective on UnitedHealth Group Incorporated (NYSE:UNH)'s stock to $325 from $400, while keeping an 'Outperform' rating, as reported by The Fly. It noted that the company reinstated 2025 adjusted-EPS guidance of $16.00-plus, which can be trough earnings, as UnitedHealth Group Incorporated (NYSE:UNH) returns to growth in 2026 and beyond. A senior healthcare professional giving advice to a patient in a clinic. The 2025 guidance assumes performance at the bottom-end or below target ranges throughout Medicare, Medicaid, Commercial, and OptumHealth segments, though the firm opines that such metrics will improve significantly over the upcoming 2 years as UnitedHealth Group Incorporated (NYSE:UNH) re-prices its respective books. The company expects moderate EPS growth in 2026, with acceleration thereafter. UnitedHealth Group Incorporated (NYSE:UNH) has updated its 2025 outlook, which includes revenues of $445.5 billion – $448.0 billion, net earnings of at least $14.65 per share, and adjusted earnings of at least $16.00 per share. This implies H1 2025 performance and expectations for the balance of the year, including higher realized and anticipated care trends. Baron Funds, an investment management company, released its Q2 2025 investor letter. Here is what the fund said: 'UnitedHealth Group Incorporated (NYSE:UNH) is a diversified health and well being company with $450 billion in annual revenue, operating across four segments: UnitedHealthcare, Optum Health, Optum lnsight, and Optum Rx. Shares fell sharply during the quarter after the company missed earnings estimates and cut its 2025 earnings per share guidance, citing higher-than-expected medical costs in its Medicare Advantage business. Investor confidence was further shaken in early May by the abrupt departure of CEO Andrew Witty and the suspension of 2025 guidance. The company also mispriced its Medicare Advantage business for 2025—a challenge compounded by reimbursement changes and an influx of newly acquired members who had not been properly risk coded. While we acknowledge UnitedHealth's potential to restore profitability in this segment over time through disciplined pricing and benefit adjustments, we chose to exit our position during the quarter in favor of other opportunities. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template
Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template

Forbes

timean hour ago

  • Forbes

Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template

The Centers for Medicare and Medicaid Services announced in July that 33 states, the District of Columbia and Puerto Rico will join a new voluntary program intended to improve patient access to and lower costs for gene therapies targeting sickle cell disease. This was a Biden administration initiative, which the Trump administration decided to continue to implement. It ties payment for two novel gene therapies to positive clinical outcomes. This could make such treatments that cost millions be more widely accessible for patients. And if successful, it may serve as a template for future cell and gene therapy agreements. Medicaid, the joint federal and state program that provides health coverage to low-income individuals, is the main insurer for SCD patients. The Biden administration announced last year that the manufacturers of Lyfgenia and Casgevy had entered into agreements with CMS to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. Essentially this means that CMS will reimburse based on whether certain agreed-upon clinical thresholds are reached in patients. According to CMS, the participating states in the newly established access initiative represent about 84% of Medicaid beneficiaries with SCD. The program could contribute towards a sizable expansion of access to potentially transformative care in the form of two extraordinarily expensive gene therapies. The launch prices for Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) were $2.2 million and $3.1 million, respectively. SCD is a group of congenital red blood cell disorders, named sickle cell for their crescent shape. The condition affects millions of people worldwide. In the United States, approximately 100,000 individuals are living with the disease, which predominantly impacts people of sub-Saharan African descent. The disease alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. As a consequence, this causes severe pain, anemia, organ damage and infections. Individuals with the disease have a shorter life expectancy, by more than 20 years on average. The most common sickle cell disorder type is sickle cell anemia. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, hydroxyurea—a bone marrow suppressive agent that decreases red blood cell production—can be used to reduce the frequency of painful episodes. It has been in use since the 1980s. The Food and Drug Administration has approved several new therapeutics in the past ten years, but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients. Gene therapies such as Lyfgenia and Casgevy are administered in an inpatient hospital setting but are considered covered outpatient drugs because they're directly reimbursed and subject to standard, federally mandated Medicaid rebates. Manufacturers of the two treatments must also provide states with supplemental rebates (post-hoc discounts off of the list price) reflecting model-negotiated terms. In turn, states are obligated to implement an agreed-upon access policy for patients. According to CMS, there is also optional federal support of up to $9.55 million per state available to help with implementation of the arrangements, outreach and data tracking. In the cell and gene therapy space, science has generally outpaced commercialization. Access to very costly treatments is a challenge. Whether in the public or commercial sector, payers must find novel ways of paying for cell and gene therapies while generating evidence with respect to their real-world effectiveness and safety. Questions insurers must find answers to include: What are the health outcomes for patients in real-world settings? Do treatments fulfill the promise of a one-time cure for certain serious illnesses or disorders? Are there particular safety concerns that appear in real-world settings? Are side effects manageable? Coordinating evidence gathering as well as contracts across state Medicaid agencies is likely to yield a more efficient process while improving access for a substantial majority of SCD sufferers nationwide. It's not just SCD gene therapies that confront a formidable set of barriers to access. All cell and gene therapy manufacturers face a challenging environment. The regulatory hurdles are enormous to begin with, but manufacturing challenges following approval are considerable, too. Furthermore, patient preparation, side effect and adverse event profiles can be intolerable. This can deter patients from signing up to initiate treatment. On top of all of this, payers concerned about the high per unit costs often impose coverage restrictions, as the Tufts Center for the Evaluation of Value and Risk in Health describes. Nonetheless, gene therapies in particular hold the promise of delivering groundbreaking improvements in health outcomes across multiple disease areas. Therefore, overcoming obstacles to optimal patient access is crucial. If successful, the SCD model being experimented with could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store